1
/
of
0
FDA Drug Approval, N216338, PACLITAXEL
FDA Drug Approval, N216338, PACLITAXEL
Regular price
$89.00 USD
Regular price
Sale price
$89.00 USD
Unit price
/
per
NDA: 216338
Company: TEVA PHARMS INC
Drug Name: PACLITAXEL
Active Ingredients: PACLITAXEL
Strength: 100MG/VIAL
Dosage Form/Route: POWDER;INTRAVENOUS
Action Date: 05/11/2023
Marketing Status: Prescription
Submission Classification: Type 5 - New Formulation or New Manufacturer
Company: TEVA PHARMS INC
Drug Name: PACLITAXEL
Active Ingredients: PACLITAXEL
Strength: 100MG/VIAL
Dosage Form/Route: POWDER;INTRAVENOUS
Action Date: 05/11/2023
Marketing Status: Prescription
Submission Classification: Type 5 - New Formulation or New Manufacturer
Couldn't load pickup availability
- Status: Pending Fast-Track Request
- Delivery: Approximately 1 to 2 weeks when the FOIA office is operating at regular capacity
NOTE: This document is not currently in our library. Upon purchase, we will request the document from the FDA FOIA office. Learn more about Fast-Track Requests here.
View full details